Celonic Group, University College London in partnership to produce protein therapeutics using CHOvolution platform
Celonic Group, a Swiss-German contract development and manufacturing organization, and University College London (UCL), UK, have set up a partnership to enable UCL to use Celonic’s CHOvolution cell expression platform for the production of therapeutic protein candidates.
Celonic Group, a Swiss-German contract development and manufacturing organization, and University College London (UCL), UK, have set up a partnership to enable UCL to use Celonic’s CHOvolution cell expression platform for the production of therapeutic protein candidates. The goal is to establish stable high-performance cell lines for the expression of recombinant human proteins and variants for planned proof of concept clinical trials.
CHOvolution is based on CHO-K1 host cell line and is suitable for a broad range of applications – from non-GMP R&D testing to GMP development and commercial market supply.
Professor Howard Clark of the UCL Institute for Women’s Health said: “Efficient GMP production of human biologicals with anti-inflammatory and immunomodulatory properties allows for rapid translation of new agents into phase 1 safety and efficacy trials and faster exploitation of UCL basic science. This platform will facilitate testing of newly developed mimics of natural innate immune defence proteins with potential to treat inflammatory lung diseases ranging from neonatal chronic lung disease in babies to asthma and chronic obstructive lung disease in adults.”
Konstantin Matentzoglu, CEO of Celonic, commented: “We are delighted to be supporting University College London with the clinical development of these novel protein therapeutics. The market-leading CHOvolution platform combined with our expertise in GMP production of recombinant proteins will help cut the time and costs required to bring these innovative therapeutics to clinical trials.”
